| 2/27 5:00 pm - 7:30 pm. MIT Enterprise Forum of CT. "Entrepreneurial Start Up: An innovative New Technology Mobile Business Intelligence Solution." Lawn Club, 193 Whitney Ave., New Haven, CT. more |
| 3/6 3:30 pm - 6:00 pm. Connecticut Venture Group. "Investing in and Growing Consumer Product Companies". Panel discussions with reception to follow. Mariott Hotel, Stamford CT. more |
| 3/19 3:00 pm - 6:00 pm. CURE and Yale OCR Present: Optherion. A BioHaven Entrepreneurship Seminar. Anlyan Center, Congress Avenue, New Haven, CT. Reception and networking to follow. more |
| 3/24 12:00 noon - 1:30 pm. UConn OTC Series. "DNA-Guided Medicine: Commercializing the New Biotechnology for Personalized Healthcare." Gualberto Ruaño, M.D., Ph.D. President and Chief Executive Officer, Genomas, Inc. Henry Low Center, UConn Health Center, Farmington, CT. more |
| 3/25 4:30 pm - 7:30 pm. Connecticut Venture Group: International Trade Workshop. Bridgeport Holiday Inn, Bridgeport. more |
| 3/26 Connecticut Innovations Annual Technology Celebration. The Aqua Turf Club, Southington, CT. more |
| 4/11 8:00 am - 6:30 pm. Healthcare 2008 at the Yale School of Management. "Whose Healthcare is it Anyway? Understanding the Patient as a Consumer." Omni Hotel, New Haven, CT. more |
| 4/16 3:30 pm - 6:00 pm. CURE and Yale OCR Present: The Next Big Idea - Creating a New Venture. A Special BioHaven Entrepreneurship Panel with Roger Longman of Windhover Publications. Reception and networking to follow. Anlyan Center, Congress Avenue, New Haven, CT. more |
| 4/23 3:00 pm - 6:00 pm. CURE and Yale OCR Present: Vidus Ocular. A BioHaven Entrepreneurship Seminar. Anlyan Center, Congress Avenue, New Haven, CT. Reception and networking to follow. more |
|  |
|
|
Sector Vital But Needs to Gear for Uncertainty
From the desk of Paul Pescatello, President and CEO of CURE
 The recent launch of Developing World Cures was one more sign, like Connecticut’s recent support of stem cell research, of the vitality and commitment of our state’s bioscience industry. The new CURE subsidiary will seek donations of compounds and intellectual property from pharmaceutical companies and research universities, in order to develop them into medicines for neglected diseases of the developing world. Meanwhile, as the economy slows and state revenues dwindle, there will be new pressures on Connecticut bioscience R&D. All of us must remain vigilant.
For the full story
|
Rib-X Tells the Story of Its Novel Antibiotics
Mix of science and business fuels attendance at CURE/Yale BioHaven Series
 Rib-X Pharmaceuticals, Inc. is focused on the design and development of novel small-molecule antibiotics for the treatment of antibiotic-resistant infections. Detailing the company's story Feb 12 in New Haven, as part of the BioHaven seminar series presented by CURE and Yale OCR, were Bob Conerly, vice president and CFO, and Erin Duffy, Ph.D., vice president, structure based drug design. The team was introduced by Michelle Bowman of series sponsor PricewaterhouseCoopers.
For the full story
|
Pescatello Reports on UK Stem Cell Facilities
Last October, at the invitation of the UK government, a delegation from Connecticut toured a variety of stem cell research facilities in the UK. Paul Pescatello, a member of the delegation, reported January 15 to the Connecticut Stem Cell Advisory Committee.
For the full story
|
Two New Companies Join UConn's TIP
Two new companies, Revegen Corp and Escientia Life Sciences, will join UConn's Technology Incubation Program, which offers space and services to start-ups. UConn has additional wet lab openings in Farmington. "This is a great opportunity for early stage firms that want to leverage their resources through a relationship with the university," says Rita Zangari, Executive Program Director of the program.
For the full story
|
CURE Member News Digest
 454 Life Sciences announces new products and software
Achillion names Olek chief medical officer
Alexion acquires Oklahoma rights
Applied Spine names Giordano chief medical officer
Bayer HealthCare gets FDA approval for RECOTHROM™
Boehringer Ingelheim completes RE-LY™ enrollment
Bristol-Myers Squibb names West to board
Carigent receives NSF grant
Cognate takes Long Wharf space
CuraGen names Cassidy CFO
Danbury Hospital names Dodge for laboratory medicine
GlaxoSmithKline reports results for Restless Legs drug
Hartford Hospital establishes Gray Cancer Center
HistoRx names Gupta CEO
Ipsogen to provide products to AstraZeneca
Johnson & Johnson CEO sees annual progress
MannKind sees inhalable insulin progress
NanoViricides reports it is on course
Neurogen completes Phase I obesity study
Pfizer CEO describes solid 2007
PhRMA supports CEO Cancer Gold Standard™
Purdue Pharma reports litigation victory
Raindance invited to World Economic Forum
Rib-X reports Phase II trials
Vion confirms FDA go-ahead on Cloretazine® trial
Webster Bank names Klaus regional VP
UConn researchers win equipment funding
Yale bioengineers target brain tumors
For the full story
|
|
|
